Table 2 |.
Drugs for the treatment and/or prevention of Covid-19. Fifteen candidate drugs target more than one druggable control hub, among which two belong to immune-related agents (in color), nine are dietary supplements (in green), and two are gonadal hormones (in blue). The drugs with "*" are under clinical trial for treating Covid-19. Detailed information is available in Table S5.
| Drug | Control hub Number | Control hub |
|---|---|---|
| Fostamatinib* | 10 | COQ8A, CLK3, CLK2, YES1, BLK, PAK5, STK3, RIPK1, PKN1, CDK4 |
| NADH* | 5 | CYB5R3, EHHADH, HIBADH, NDUFB7, IMPDH1 |
| Calcium phosphate dihydrate | 3 | S100A13, PEF1, CATSPER1 |
| Calcium Citrate | 3 | S100A13, PEF1, CATSPER1 |
| Calcium Phosphate | 3 | S100A13, PEF1, CATSPER1 |
| Conjugated estrogens* | 2 | SLC10A1, COMT |
| Progesterone* | 2 | SLC10A1, SULT2B1 |
| Phenethyl Isothiocyanate | 5 | HNRNPF, TPM1, |
| Ademetionine | 3 | COMT, GNMT, MAT2A |
| Copper | 2 | AHCY, CYB5R3 |
| Aspartic acid | 2 | ASPH, ACY3 |
| Methionine | 2 | GLUL, MAT2A |
| Citric acid | 2 | HGS, GNMT |
| Liothyronine | 2 | PCNA, SLC10A1 |
| Liotrix | 2 | SLC10A1, SLC16A2 |